Anthem Inc

Our Anthem and Humana fair value estimates get a boost.

With more than a dozen open-end and exchange-traded offerings launched this year, we examine the ones to consider.

We see risks for managed care but also opportunities to own moatworthy companies at sizable discounts.

We see opportunity within the consumer cyclical sector.

Funds from Vanguard, PIMCO, and T. Rowe Price are among the ratings boosts.

These narrow-moat stocks all have negative moat trends and are trading at 1- or 2-star levels.

For now, we’re not changing our valuations or moat ratings for the affected companies.

Valuations in the healthcare sector in aggregate look fair, increasing the importance on stock selection where innovation and redeployment of capital weigh heavily.

Gold-rated Dodge & Cox Stock’s seasoned team, low fees, and decisive value approach have led to enviable long-term results.

Silver-rated Oppenheimer Global fishes globally for growth ideas.

John Linehan, manager of the Bronze-rated T. Rowe Price Equity Income, has generated fine results since taking over for the retiring Brian Rogers in late 2015.

The PBM has unparalleled supplier pricing power and scale advantages.

Overblown concerns over drug pricing in the U.S. are creating attractive valuations for the more innovative drug companies.

A trio of Morningstar analysts share their outlooks for and opportunities in the healthcare, consumer, and basic materials sectors.

Continued worries about Anthem’s lawsuit have created a buying opportunity in the pharmacy benefit manager, says Morningstar’s Matt Coffina.

It's a record year for M&A deals in corporate America. Contributor John Waggoner explains what that means for investors.

China fears and Fed uncertainty sent markets lower in the third quarter, but stocks still aren't cheap.

Consolidation activity in the sector will have a positive impact operationally, but the stocks are overpriced, says Morningstar's Vishnu Lekraj.

The combination should boost long-term economic profitability but Anthem is significantly overpaying for this transaction, writes Morningstar’s Vishnu Lekraj.

Curtain coming down on Greek tragedy.